Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alcuronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.98 |
| ▸ | CHRNA7 | P36544 | 14/20 | 0.98 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | HTR3A | P46098 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcuronium SCHEMBL1649633 | 1.00 | CHRNA7 (0.98) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Alcuronium SCHEMBL150079 | 0.99 | CHRNA7 (1.00) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Alcuronium SCHEMBL30817419 | 0.98 | CHRNA7 (0.98) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Hydrochloric Acid SCHEMBL31650965 | 0.83 | CHRNA7 (1.00) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Bisnordihydrotoxiferine SCHEMBL29525342 | 0.60 | CHRNA7 (0.56) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Isostrychnine SCHEMBL29898321 | 0.57 | CHRNA7 (0.43) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| SCHEMBL31237286 | 0.54 | GLRA1 (0.39) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| SCHEMBL20495361 | 0.44 | ALDH1A1 (0.43) | — | |
| SCHEMBL19949789 | 0.43 | ADRA1D (0.42) | — | |
| SCHEMBL2571298 | 0.43 | ADRA1D (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 756 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | GEORGETOWN UNIVERSITY (US) | 2026-03-26 | — | — | US | claimed |
| CN-115282114-B | Soluble microneedle formula of recombinant protein medicine, application of soluble microneedle formula, microneedle and preparation method of soluble microneedle | 珠海科瑞微医药科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| CN-1703199-A | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG (DE) | 2005-11-30 | — | — | CN | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| JP-7233050-A | — | — | None | — | — | JP | disclosed |
| US-20260117282-A1 | High Throughput Cell-Based Screening For Aptamers | MEIRAGTX GENE REGULATION LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-0239690-A2 | Method and apparatus for measuring aggregation rate of whole blood red blood cells | Tomita, Minoru, Dr., (JP) | 1987-10-07 | — | — | EP | disclosed |
| US-4675323-A | SLEEP INDUCING HYPNOTIC, ANTIULCER ANDOR ANTICONVULSANT AGEN T, ANALGESICS | SYNTHELABO (FR) | 1987-06-23 | — | — | US | disclosed |
| US-4650796-A | ANXIOLYTIC, HYPNOTIC, ANTICONVULSANT, ANALGESIC, ANTIULCER | SYNTHELABO (FR) | 1987-03-17 | — | — | US | disclosed |
| US-4190657-A | ANTI-ANOXIA AND PSYCHOTROPIC ACTIVITY | SYNTHELABO (FR) | 1980-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117282-A1 | High Throughput Cell-Based Screening For Aptamers | CPSF6, TIA1, UPF1 | CHRM2 4805/4885CHRNA7 4440/4885CHRNA4 4194/4885 |
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | PAX3, FOXO1, PAXBP1 | CHRM2 2002/4885CHRNA7 2245/4885CHRNA4 3040/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | CHRM2 2986/4885CHRNA7 4391/4885CHRNA4 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.